Latest research on Valsartan

Valsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.

Valsartan interactions

In addition to dabigatran, the other medications included verapamil, Budesonide, Valsartan, and hydrochlorotiazide. [source, 2016]
Losartan and Valsartan, both ARBs, have been proven to be “not inferior” to Captopril, an ACEI, in patients with AMI and heart failure and/or LV systolic dysfunction [8-10]. [source, 2016]
In AMI patients with heart failure and/or LV dysfunction, the efficacy of ARBs compared to ACEIs for secondary prevention of MACEs has been tested in two large-scale randomized clinical studies (RCTs): OPTIMAAL (Optimal Trial in Myocardial Infarction with Angiotensin II antagonist Losartan) and VALIANT (Valsartan in Acute Myocardial Infarction Trial) [8,10]. [source, 2016]
In VALIANT, Valsartan was “non-inferior” to Captopril in patients with high risk for MACE after AMI. [source, 2016]
In the present study, we excluded patients who had already received ACEIs or ARBs before hospitalization, whereas in VALIANT, 39.4% of the Valsartan group and 38.5% of the Captopril group received non-study ACEIs for an average of 5 days after the AMI, but before randomization [10]. [source, 2016]
Irbesartan, Candesartan and Valsartan displayed high concentration (Table 6). [source, 2016]
In rodent models of Alzheimer’s disease, sartans (Candesartan, Losartan, Valsartan and Telmisartan) ameliorate all risk factors for human Alzheimer’s disease, including protecting cerebral blood flow and cognition during stroke, decreasing inflammation and Aβ neurotoxicity, and reducing traumatic brain injury [24, 26, 27, 30–37]. [source, 2016]
The recent PARADIGM-HF multicenter randomized controlled trial [116] tested a drug that is a combination of the ARB Valsartan and the neprilysin inhibitor sacubitril on 8399 patients with heart failure and a reduced LVEF, reporting a reduction of 20% in death from cardiovascular causes or hospitalization for heart failure as compared with the ACE inhibitor Enalapril alone at maximum dosage (p < 0.001). [source, 2016]
The patient was taking Valsartan 160 mg/day and Amlodipine 10 mg/day for hypertension. [source, 2016]
Rats were categorized into 7 groups, as follows: 1) vehicle control that was administered sterile deionized water icv (n = 7); 2) icv-administered Ang II (0.01, 0.02, and 0.07 nmol per rat; n = 7); 3) 10 nmol Valsartan (3 μl) icv-administered before icv-administration of Ang II (n = 5); 4) 100 nmol PD123319 (5 μl) icv-administered before icv-administration of Ang II (n = 5); 5) 100 nmol Valsartan (200 μl) iv-administered before icv-administration of Ang II (n = 5); 6) 100 nmol PD123319 (200 μl) iv-administered before icv-administration of Ang II (n = 5); and 7) ADX with Hydrocortisone (5 mg/kg per rat, intramuscular injection) administered before icv-administration of Ang II (n = 4). [source, 2016]